Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy
Authors:ID Vrankar, Martina (Author)
ID Zwitter, Matjaž (Author)
ID Kern, Izidor, Klinika Golnik (Author)
ID Stanič, Karmen (Author)
Files:URL URL - Source URL, visit http://www.elis.sk/download_file.php?product_id=5518&session_id=kocugv6art3ltib4t6te7tjam3
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:The standard treatment for inoperable locally advanced non-small cell lung cancer (LA NSCLC) includes concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Long term survival rates with these approaches remains only in the order of 15%, therefore new treatment strategies, including immunotherapy, are under investigation, with programmed death ligand-1 (PD-L1) as one of the major players. We evaluated the clinical significance of PD-L1 expression in tumor samples from patients with inoperable LA NSCLC who underwent concurrent chemoradiotherapy (CRT) in our institution between 2005 and 2010 and correlated their expression with clinicopathological parameters and outcome of treatment. Among 107 patients treated with concurrent CRT, a total of 43 (36 males and 7 females) had sufficient tissue for immunohistochemical (IHC) staining. The expression of PD-L1 was demonstrated in 7 tumors, in 6 males and 1 female. No statistical significant differences in patient characteristics, including age, smoking status and gender, were found according to the PD-L1 expression. After a median follow up of 103.6 months, median progression free survival (PFS) was 19.9 months in patients without and 10.1 months in patients with PD-L1 expression (p=0.008). Median overall survival (OS) was 28.4 and 12.1 months for PD-L1 negative and PD-L1 positive patients, respectively (p=0.012). In conclusions, patients with PD-L1 expression had shorter PFS and OS after concurrent CRT in LA NSCLC. Unfortunately, only small number of patients had tissue available for the IHC testing, therefore no firm conclusions could be made and further investigation is warranted.
Keywords:non-small cell lung cancer, lung cancer, chemoradiotherapy, survival
Publication status:Published
Publication version:Version of Record
Place of publishing:Slovaška
Publisher:AEPress
Year of publishing:2018
Number of pages:str. 140-146
Numbering:Vol. 65, no. 1
PID:20.500.12556/DiRROS-12920 New window
UDC:616.2
ISSN on article:0028-2685
DOI:10.4149/neo_2018_170206N77 New window
COBISS.SI-ID:2806907 New window
Publication date in DiRROS:17.12.2020
Views:2348
Downloads:580
Metadata:XML DC-XML DC-RDF
:
VRANKAR, Martina, ZWITTER, Matjaž, KERN, Izidor and STANIČ, Karmen, 2018, PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Neoplasma [online]. 2018. Vol. 65, no. 1, p. 140–146. [Accessed 23 March 2025]. DOI 10.4149/neo_2018_170206N77. Retrieved from: http://www.elis.sk/download_file.php?product_id=5518&session_id=kocugv6art3ltib4t6te7tjam3
Copy citation
  
Share:Bookmark and Share


Searching for similar works...Please wait....
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Neoplasma
Publisher:Cancer Research Institute of the Slovak Academy of Sciences
ISSN:0028-2685
COBISS.SI-ID:26004480 New window

Secondary language

Language:Undetermined
Keywords:nedrobnocelični rak, pljučni rak, kemoradioterapija, preživetje


Back